Adaptive Biotechnologies Corporation Common Stock (ADPT)

About ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

624

Website

www.adaptivebiotech.com

Fundamentals

1-day range

$25.13$26.46

Market cap

$3.77B

P/E (trailing)

—

P/E (forward)

-136.36

EPS (trailing)

$-0.41

Dividend yield

—

Beta

2.14

Avg. volume

2.97M

Forecasts

7 analyst ratings

Adaptive Biotechnologies Corporation Common Stock Competitors

Chosen by industry and closest market cap.

• ADPT

  Adaptive Biotechnologies Corporation Common Stock

  $25.19

  ▼ 4.73%
  Market cap $3.77BP/E —
  $12$26.87
• RLAY

  Relay Therapeutics Inc. Common Stock

  $18.78

  ▼ 3.30%
  Market cap $3.78BP/E —
  $3.5$21.27
• KOD

  Kodiak Sciences Inc Common Stock

  $37.77

  ▼ 3.45%
  Market cap $2.84BP/E —
  $8.29$47.84
• BEAM

  Beam Therapeutics Inc. Common Stock

  $29.31

  ▼ 3.84%
  Market cap $2.81BP/E —
  $16.02$38.26
• TARS

  Tarsus Pharmaceuticals Inc. Common Stock

  $71.84

  ▼ 0.12%
  Market cap $2.81BP/E —
  $48.2$85.25
• CRSP

  CRISPR Therapeutics AG Common Shares

  $57.69

  ▼ 2.84%
  Market cap $4.99BP/E —
  $44.12$78.48
• COAG

  Hemab Therapeutics Holdings Inc. Common Stock

  $44.77

  ▼ 9.55%
  Market cap $2.44BP/E —
  $23$55.42

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5
  Benzinga · 8/4/2026
• Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder
  SeekingAlpha · 7/31/2026

• OWEN KATEY EINTERZ · August 26, 2026 · Sale

  9.6K @ $26
• Susan Bobulsky · August 10, 2026 · Sale

  3.0K @ $25
• Susan Bobulsky · July 30, 2026 · Sale

  1.3K @ $24
• Harlan S. Robins · July 21, 2026 · Option Exercise

  284.8K @ $6.55
• Harlan S. Robins · July 21, 2026 · Sale

  213.7K @ $22.12
• Harlan S. Robins · July 21, 2026 · Sale

  278.7K @ $21.72
• Susan Bobulsky · July 16, 2026 · Sale

  5.0K @ $23
• Francis Lo · July 15, 2026 · Option Exercise

  22.7K @ $8.46
• Francis Lo · July 15, 2026 · Option Exercise

  23.7K @ $12.14
• Francis Lo · July 15, 2026 · Option Exercise

  59.4K @ $7.8
• Francis Lo · July 15, 2026 · Sale

  105.8K @ $22.59
• Harlan S. Robins · July 2, 2026 · Sale

  146.9K @ $22.45
• Harlan S. Robins · July 2, 2026 · Sale

  239.4K @ $21.74
• Francis Lo · July 2, 2026 · Option Exercise

  12.6K @ $8.46
• Francis Lo · July 2, 2026 · Option Exercise

  12.6K @ $12.14

Institutional Ownership

March 31, 2026

Total shares held

145.26M

Total value held

$1.92B

Institutional holders

287